Current Assets
Accounts Receivable
Eli Lilly Accounts Receivable increased by 3.8% to $18.43B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 53.1%, from $12.04B to $18.43B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 24.8% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Rapid growth relative to sales may indicate collection issues or aggressive revenue recognition; stability suggests efficient cash conversion.
Detailed definition
This represents the total amount owed to the company by customers for goods or services delivered, minus the allowance f...
Peer comparison
Standard metric for all companies with B2B or credit-based sales models.
Metric ID:
accounts_receivable_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.83B | $5.91B | $6.67B | $6.32B | $6.36B | $6.72B | $6.90B | $7.53B | $7.52B | $8.17B | $9.09B | $7.89B | $11.03B | $10.29B | $11.01B | $12.04B | $14.17B | $16.11B | $17.76B | $18.43B |
| QoQ Change | — | +1.5% | +12.8% | -5.2% | +0.7% | +5.5% | +2.7% | +9.1% | -0.1% | +8.7% | +11.3% | -13.3% | +39.8% | -6.6% | +6.9% | +9.4% | +17.7% | +13.7% | +10.3% | +3.8% |
| YoY Change | — | — | — | — | +9.2% | +13.5% | +3.3% | +19.0% | +18.1% | +21.6% | +31.8% | +4.8% | +46.7% | +26.1% | +21.1% | +52.6% | +28.5% | +56.5% | +61.4% | +53.1% |
Range$5.83B – $18.43B
CAGR+27.4%
Avg YoY Growth+29.2%
Median YoY Growth+23.8%
Current Streak6 quarters growth
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Eli Lilly's accounts receivable?
- Eli Lilly (LLY) reported accounts receivable of $18.43B in Q1 2026.
- How has Eli Lilly's accounts receivable changed year-over-year?
- Eli Lilly's accounts receivable increased by 53.1% year-over-year, from $12.04B to $18.43B.
- What is the long-term trend for Eli Lilly's accounts receivable?
- Over 5 years (2020 to 2025), Eli Lilly's accounts receivable has grown at a 24.8% compound annual growth rate (CAGR), from $5.88B to $17.76B.
- What does accounts receivable mean?
- The net amount of money owed by customers after accounting for potential non-payments.